作者
Mahmut Ilker Yilmaz, Alper Sonmez, Mutlu Saglam, Halil Yaman, Selim Kilic, Tayfun Eyileten, Kayser Caglar, Yusuf Oguz, Abdulgaffar Vural, Mujdat Yenicesu, Francesca Mallamaci, Carmine Zoccali
发表日期
2012/2/1
期刊
American journal of kidney diseases
卷号
59
期号
2
页码范围
177-185
出版商
WB Saunders
简介
BACKGROUND
Fibroblast growth factor 23 (FGF-23) is a marker of endothelial dysfunction and atherosclerotic complications in patients with chronic kidney disease (CKD). Because previous studies suggested that sevelamer may exert effects on FGF-23 level and endothelial function independently of its phosphate-lowering action, we tested the effect of sevelamer versus calcium acetate on vascular function and FGF-23 levels.
STUDY DESIGN
Randomized prospective open-label trial.
SETTING & PARTICIPANTS
Patients with stage 4 CKD with hyperphosphatemia (n = 100).
INTERVENTION
An 8-week intervention with sevelamer (n = 47) and calcium acetate (n = 53).
OUTCOMES
The primary study outcome was change in flow-mediated vasodilatation in the forearm. The secondary outcome was change in FGF-23 levels.
RESULTS
Serum phosphate levels decreased in both treatment arms (P < 0.001), but more …
学术搜索中的文章
MI Yilmaz, A Sonmez, M Saglam, H Yaman, S Kilic… - American journal of kidney diseases, 2012
